
    
      This is a prospective, open-label, multi-center, single-arm clinical trial aimed at patients
      with advanced non-small cell lung cancer (NSCLC) with asymptomatic brain metastases with
      epidermal growth factor receptor sensitive mutations (EGFRm+) who have not received any
      systemic treatment To evaluate the effectiveness and safety of high-dose almonertinib
      mesylate.Eligible patients were included in the high-dose almonertinib treatment group and
      received oral almonertinib 165 mg once a day.
    
  